Prothena Reports Third Quarter 2022 Financial Results and Business Highlights

Net cash used in operating and investing activities was $31.3 million in the third quarter and $104.2 million for the first nine months of 2022; quarter-end cash and restricted cash position was $497.0 millionPhase 3 VITAL study data on observed survival benefit in Mayo Stage IV AL amyloidosis patients treated with...

Related Keywords

United States ,American ,Jennifer Zibuda ,Novo Nordisk ,International Symposium On Amyloidosis ,Investor Relations Communications ,Nasdaq ,Company On Twitter Prothenacorp ,Exchange Commission ,American Society Of Hematology ,Bristol Myers Squibb ,Prothena Corporation ,Mayo Stage ,Gene Kinney ,Chief Executive Officer ,Recent Business Highlights ,Monday December ,Annual Meeting ,Survival Benefit ,Consistent After Adjustment ,Healthcare Conference ,Annual Denver Biopharma Summit ,First Nine Months ,Quarterly Report ,Investor Relations ,